Concomitant suppression of COX-1 and COX-2 is insufficient to induce enteropathy associated with chronic NSAID use

Kayla Barekat,Emanuela Ricciotti,Soumita Ghosh,Christin Herrmann,Karl Keat,Charles-Antoine Assenmacher,Ceylan Tanes,Naomi Wilson,Arjun Sengupta,Ujjalkumar S Das,Marylyn Ritchie,Kyle Bittinger,Aalim Weljie,Ken Cadwell,Frederic Bushman,Gary Wu,Garret A FitzGerald
DOI: https://doi.org/10.1101/2024.11.22.624882
2024-11-25
Abstract:Nonsteroidal anti-inflammatory drugs (NSAIDs) are the most widely used medications for the management of chronic pain; however, they are associated with gastrointestinal (GI) adverse events. Although many mechanisms have been suggested, NSAID-induced enteropathy has been thought mainly due to inhibition of both cyclooxygenases (COX) -1 and -2 resulting in suppression of prostaglandin synthesis. Surprisingly, over 10 months, concomitant postnatal deletion of Cox-1 and -2 failed to cause intestinal injury in mice unless they were treated with naproxen or its structural analog, phenylpropionic acid, which is not a COX inhibitor. Cox double knockout mice exhibit a distinct gut microbiome composition and cohousing them with controls rescues their dysbiosis and delays the onset of NSAID-induced GI bleeding. Suppression of bile acid synthesis is also protective. In both the UK Biobank and All of US, coadministration of antibiotics with NSAIDs is associated with an increased frequency of GI bleeding. These results show that prostaglandin suppression plays a trivial role in NSAID-induced enteropathy. However, Cox deletion causes dysbiosis of the gut microbiome that amplifies the enteropathic response to NSAIDs.
Pharmacology and Toxicology
What problem does this paper attempt to address?